甲状腺激素通过调节大鼠和小鼠小肠中的SGLT1表达来调节食后葡萄糖代谢
Shunichi Matsumoto1, Satoshi Yoshino1, Shuichi Okada1
1Department of Internal Medicine, Division of Endocrinology and Metabolism, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
International journal of molecular sciences
|September 27, 2025
概括
甲状腺激素通过增加/葡萄糖共运输体1 (SGLT1) 的表达来促进小肠中的葡萄糖吸收. 这种机制有助于食后高血糖症,为糖尿病管理提供了新的见解.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 代谢研究研究 代谢研究
背景情况:
- 甲状腺功能障碍改变了新陈代谢,增加了基础代谢率和葡萄糖吸收.
- 甲状腺激素影响葡萄糖代谢,但食后高血糖症的机制尚未完全理解.
研究的目的:
- 研究甲状腺激素在调节小肠中的/葡萄糖共运输体1 (SGLT1) 表达中的作用.
- 为了确定甲状腺激素介导的SGLT1调节对食后葡萄糖代谢的影响.
主要方法:
- 检查了小鼠小肠中的甲状腺激素受体分布.
- 评估了甲状腺素 (T4) 治疗对大鼠和转基因小鼠模型中SGLT1表达的影响.
- 在口服和腹腔内葡萄糖管理后评估的食后葡萄糖水平.
主要成果:
- 甲状腺素 (T4) 治疗显著上调SGLT1表达在远端小肠.
- 增加SGLT1表达与口服葡萄糖摄入后食后葡萄糖水平升高相关.
- 抗甲状腺激素的小鼠 (TRβΔ337T) 显示SGLT1表达增加和食后高血糖症.
结论:
- 甲状腺激素通过上调SGLT1表达来增强肠道葡萄糖的吸收.
- 这种机制有助于甲状腺激素诱导的食后高血糖症.
- 这些发现表明,在糖尿病中管理高血糖症的新型治疗标.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Glucose Homeostasis: Regulation of Blood Glucose
3.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Glucose Absorption Into the Small Intestine
35.0K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
35.0K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600


